Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2025 May 9:15:1537825.
doi: 10.3389/fonc.2025.1537825. eCollection 2025.

Case Report: Acral vasculitis induced by Immune Checkpoint Inhibitors: a case series and literature review

Affiliations
Case Reports

Case Report: Acral vasculitis induced by Immune Checkpoint Inhibitors: a case series and literature review

Valérian Rivet et al. Front Oncol. .

Abstract

Introduction: Immune Checkpoint Inhibitors (ICIs) may cause various immune- related Adverse Events (irAEs). Of these events, vascular involvement is still considered an uncommon irAEs and generally concerns large or medium vessels. Acral small-vessel vasculitis can lead to severe digital necrosis.

Case presentation: Herein, we present three cases after treatment with pembrolizumab, nivolumab, and combination nivolumab/ipilimumab for lung adenocarcinoma, renal cell carcinoma, and melanoma, respectively. Two patients had a Raynaud's-like syndrome. All of them presented with digital ischemia of both hands and with severe acral necrosis in the first case. Management consisted in ICI discontinuation, high-dose steroids, and vasodilator agents with good evolution in the three cases. No rechallenge of ICI has been attempted.

Discussion: We found 12 other cases in the literature review to build a cohort of 15 patients, mostly male with a median age of 60 years. Lung cancer and melanoma are the most common tumors. The most frequently used ICI was pembrolizumab. The median time to onset was 8 weeks. The main clinical presentation was a distal and painful necrosis mostly on thehands with bilateral involvement. Toes were affected in only two cases. All cases were severe features with grade ≥ 3. Eleven patients were treated with steroids and vasodilator agents. ICI was discontinued permanently in all patients.

Conclusion: ICI-induced small-vessel vasculitis can lead to severe digital ischemia, often in males, and is preceded by a Raynaud's-like syndrome with mostly bilateral and hand involvement. Data are still missing to optimize management of these kinds of patients.

Keywords: acral vasculitis; immune checkpoint inhibitors; immune-related adverse events; ipilimumab; nivolumab; pembrolizumab.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Main clinical and imaging features of the case series. Digital necrosis of case 1 (A, B), diffuse interstitial pneumonia of case 1 (C, D), and bilateral digital ischemia of both hands of case 2 (E, F).

References

    1. Daxini A, Cronin K. Sreih AG.Vasculitis associated with immune checkpoint inhibitors-a systematic review. Clin Rheumatol. (2018) 37:2579–84. doi: 10.1007/s10067-018-4177-0 - DOI - PubMed
    1. Padda A, Schiopu E, Sovich J, Ma V, Alva A, Fecher L. Ipilimumab induced digital vasculitis. J Immunother Cancer. (2018) 12:12. doi: 10.1186/s40425-018-0321-2 - DOI - PMC - PubMed
    1. Le Burel S, Champiat S, Mateus C, Marabelle A, Michot JM, Robert C, et al. . Prevalence of immune-related systemic adverse events in patients treated with anti-Programmed cell Death 1/anti-Programmed cell Death-Ligand 1 agents: A single-centre pharmacovigilance database analysis. Eur J Cancer. (2017) 82:34–44. doi: 10.1016/j.ejca.2017.05.032 - DOI - PubMed
    1. Khaddour K, Singh V, Shayuk M. Acral vascular necrosis associated with immune-check point inhibitors: case report with literature review. BMC Cancer. (2019) 19:449. doi: 10.1186/s12885-019-5661-x - DOI - PMC - PubMed
    1. Yohannan B, Truly T, Kala J, Jafri SH. Pembrolizumab-induced acral vasculitis. J Immunother. (2023) 46:107–10. doi: 10.1097/CJI.0000000000000457 - DOI - PubMed

Publication types

LinkOut - more resources